Paris (France), April 28, 2023 – 9.00 pm CEST - Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter “Onxeo” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced the publication of the Company’s 2022 annual financial report.

The 2022 annual financial report is available to the public on the Company’s website.

• Download the full press release